Cases, + 216,850

Deaths, + 1,183 = 174,308

Vaccinations, 117,223,509

Infection drivers


Markets and malls have reopened

Transport operating at full capacity

Big weddings


Election rallies

Probable new variants


Population 9.3 million

US and UK vaccination rates

UK, 48% of overall population

I guess the difference won’t bother most news consumers much but I’d like to think your viewers might be more discerning, (Tony)

Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID -19 cases and a comparison with 489,871 people receiving a COVID -19 mRNA vaccine

Can help contextualize the risks and benefits of vaccination in this regard

Using an electronic health records network

Absolute incidence of cerebral venous thrombosis (CVT) in the two weeks following:

(Incidence of portal vein thrombosis, PVT also assessed)

COVID-19 diagnosis (N=513,284)

Influenza (N=172,742)

Receipt of the BNT162b2 (Pfizer) or mRNA-1273 (Moderna) COVID-19 vaccines (N=489,871)

The incidence of CVT after COVID-19 diagnosis

CVT = 39.0 per million people

The incidence of CVT after influenza diagnosis

CVT = Zero per million people

Incidence of CVT after receiving BNT162b2 or mRNA-1273 vaccine

CVT = 4.1 per million people

The incidence of PVT after COVID-19 diagnosis

PVT = 436

The incidence of PVT after influenza diagnosis

PVT = 98

Incidence of PVT after receiving BNT162b2 or mRNA-1273 vaccine

PVT = 44 per million

CVT incidence observed across the entire health records network

0.41 per million people over any 2-week period

Laboratory test results, available in a subset of the COVID-19 patients, suggestive of:

Raised D-dimer, lowered fibrinogen, and an increased rate of thrombocytopenia in the CVT and PVT groups

CVT Mortality = 20% in 2 weeks after CoViD
PVT mortality = 18.8% in 2 weeks after CoViD

Latest estimate from the European Medicines Agency

Incidence associated with ChAdOx1 nCoV-19 vaccine

CVT = 5.0 per million people

Splanchnic thrombosis by the EMA following vaccination with ChAdOx1

(portal, splenic, mesenteric)

53 cases out of 34 million people

1.6 per million people